Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients

This study tests letermovir, an antiviral pill taken once daily, as a way to prevent cytomegalovirus (CMV) from coming back in solid organ transplant recipients (heart, kidney, or liver) who have already been treated for a CMV infection or disease. CMV is a common virus that can cause serious illness in transplant patients because their immune system is suppressed, and preventing recurrence is a major challenge. Adult transplant recipients (over 18) who have completed CMV treatment and whose doctor believes they need preventive therapy are eligible, provided they have adequate kidney and liver function and are not on dialysis. Participation involves taking letermovir 480 mg once daily for 60 days, with blood tests to monitor immune response, and follow-up visits for 4 months after stopping the drug to check for relapse. This summary was prepared using AI to help patients understand the study in plain language.